Lisata Therapeutics Inc
LSTA
Company Profile
Business description
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
Contact
110 Allen Road
2nd Floor
Basking RidgeNJ07920
USAT: +1 908 842-0100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
Ask the analyst: Could Endeavour suffer from lower booze consumption and tighter gambling rules?
Could health concerns and legislation pose a threat to Australia's biggest liquor retailing and gaming group? Our analyst Johannes Faul has his say.
stocks
Should you avoid this highflying ASX share?
A sound business model but the shares are expensive.
stocks
ASX gold play to take advantage of surging prices
Strong results on the back of elevated gold prices.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,341.30 | 21.80 | -0.26% |
| CAC 40 | 8,173.75 | 125.83 | 1.56% |
| DAX 40 | 23,081.03 | 754.22 | 3.38% |
| Dow JONES (US) | 43,006.59 | 485.60 | 1.14% |
| FTSE 100 | 8,755.84 | 3.16 | -0.04% |
| HKSE | 23,594.21 | 652.44 | 2.84% |
| NASDAQ | 18,552.73 | 267.57 | 1.46% |
| Nikkei 225 | 37,796.61 | 378.37 | 1.01% |
| NZX 50 Index | 12,413.02 | 0.95 | 0.01% |
| S&P 500 | 5,842.63 | 64.48 | 1.12% |
| S&P/ASX 200 | 8,112.90 | 28.20 | -0.35% |
| SSE Composite Index | 3,341.96 | 17.75 | 0.53% |